Giannis Mountzios, Director of 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared a post on X:
“It’s official. Tarlatamab improves overall survival over SoC chemotherapy in pre-treated patients with advanced SCLC. A major breakthrough for a devastating disease after decades of failed trials.
Stay tuned for full data coming soon.”
